Abstract
Provisional patent specification for USPTO filing. Discloses computational methods for drug repurposing in ulcerative colitis (UC) using single-cell RNA sequencing of colonic biopsies from 4 UC patients (inflamed), 4 UC self-controls (non-inflamed paired), and 4 healthy controls, variational autoencoder-based dimensionality reduction (scVI), Leiden clustering, Wilcoxon differential expression (UC vs HC primary, plus epithelial, immune, plasma cell, and pro-UC cluster subsets), and LINCS L1000 transcriptomic reversal scoring. Application to GSE231993 across 33 independent Enrichr queries identified 303 NOVEL_ALL candidates (56% of assessed compounds). Top candidates: AMG-232 (MDM2 inhibitor, priority 815,012), SAR405838 (MDM2 inhibitor, 787,447), R-547 (CDK inhibitor, 570,989), RG-7388 (MDM2 inhibitor, 466,170), GW-9662 (PPARγ antagonist, 377,523), TAK-733 (MEK1/2 inhibitor, 307,363), LXR-623 (LXR agonist, 49,934). Five MDM2 inhibitors in the top 15 — the densest single-mechanism cluster across the inventor's ten-pipeline series — implicate a p53-MDM2-colonocyte differentiation axis as a novel UC therapeutic target. R-547 achieves four-pipeline NOVEL_ALL consistency. Inventor: Glen Charles Ritschel, Ritschel Research, Tega Cay, SC. Micro-entity filing.